

National Genomic Testing Process

Document Purpose

This diagram has been developed within the national interoperability project for the GMS. The purpose of the operational flow is to provide the visual reference points against which data requirements can be stated.

Synopsis – Principles Applied

This diagram illustrates a nationally applicable, generic process occurring between the requesting of genomic tests and the subsequent receipt of result reports. The scope of the diagram is held strictly between these events. To achieve this, the operational task sequence depicted is solution and location agnostic. Therefore, the diagram does not illustrate lower levels of detail inside organisational boundaries, which may differ between locations.

The diagram is presented from the perspective of the originating/Home GLH of the test request. Additionally, the process represents the task sequence applicable per test.

Finally, the diagram demonstrates how the Home GLH may be the facilitator of a specialist test or interpretation on behalf of a remote requestor.

Version Control

Version	Date	Modifier	Comments/Updates
0.1	11.02.22	M Price	Initial draft – SE_GLH process flow lifted into BPMN template- method and style adjustment. Process and sequence updates applied.
0.2	14.02.22	M Price	Interpretation & Report expanded sub processes added
0.3	17.02.22	M Price	Variant Identification process steps added, Reflex Testing placement adjusted. Validation of draft (with Subject Matter Experts) to commence from this version onwards. Extensive updates planned for subsequent drafts.
0.4-05	10.03.22	M Price	Review and updates via Clinical Directors (Cancer pathways) + Further informatics input driven amendment.
0.6	17.03.22	M Price	Error paths added/developed + minor amends. DPYD scenario added (new slide)
0.7	28.03.22	M Price	Copy is post Informatics review 28 th Mar. WGS Scenario slide added. Further updates and validation now planned. Minor amendments include:- various terminology updates, additional decision point in error flow. Counterpart documents to update also.
0.8	04.04.22	M Price	Reference labels added and updated to align with data counterpart document
0.9	29.04.22	M Price	Minor amends following Scientific Advisors and Ops Directors reviews - 5.11.1 task added, 3.01 – 3.05 sequence revised.
0.9.1	06.05.22	M Price	Task 3.02 sequences updated, intermediate events adjusted.
0.9.2	26.05.22	M Price	DPYD & WGS copies uplifted to match current master diagram.
0.9.3	01.07.22	M Price	Copy Approved @ GOMT. Minor labelling amendment at 2.09.
1.0	10.10.22	M Price	Baselined – draft stable

BPMN & General KEY



Start Event: – Indicates the event that triggers the start of the process.



End Event – Indicating the event that occurs, marking the end points of either sub processes of the main process flow.



Intermediate Event – Represents any notable event that occurs between the start and end events.



Intermediate Timer – Indicates a time constraint applicable to a task.



Gateway: Parallel – Depicts commencement of tasks occurring in parallel. Follow-on instances ensure that parallel tasks complete prior to the next task in the flow commencing.



Gateway: Either/Or – Indicating the process flow will only follow one of the subsequent attached flows.



Gateway: Inclusive – Present when one or more flows can be followed optionally. The second, merging instance serves to ensure all active sequences complete prior to any subsequent task commencing.



Sub Task: Collapsed – Indicates a task that is comprised of a series of sub-tasks, which are linked to within the document and expanded in a separate page.



Sub Task: Expanded – Used to contain the expanded view of sub process tasks.



Sequence Flows:– Indicate and connect the general flow between tasks, gateways and events. Additional markers are used, such as the forward slash, which depicts the default flow, where multiple flows are present.



Message Flows: – Serves as the bridging link between tasks in separate pools or lanes, and indicates the flow of messages between tasks.

Document Validation

This document has been validated by providing communities-of-interest, with the opportunity to review and feedback. A combination of interviews and workshops has been held with Operational, Scientific and Informatics stakeholders. The following, non-exhaustive list of roles is applicable. The document has been exposed to multiple stakeholders from each region engaged in the GMS.

- Director of Operations
- Deputy Operations Lead for Clinical Bioinformatics
- GLH Bioinformatics Lead
- Deputy Directors to the GU
- Scientific Director
- Consultant Clinical Scientist Lead
- Principal Clinical Scientist
- Consultant Clinical Scientist
- Clinical Scientist
- Consultant in Clinical Genetics
- Laboratory Lead for Precision Medicine
- Cardiologist
- Scientific Advisor to the GU
- Informatics lead
- IT Manager





